Parameters | Hazard ratio (95% C.I.) | P-value | |
---|---|---|---|
LINE-1 methylation status | 0.017 | ||
Q4 (n = 43) | Reference | ||
Q3 (n = 43) | 1.575 (0.561–4.602) | 0.320 | |
Q2 (n = 43) | 3.369 (1.328–8.551) | 0.011 | |
Q1 (n = 43) | 3.400 (1.349–8.570) | 0.009 | |
LINE-1 methylation status | Q3, Q4 (n = 86) | ||
Q1, Q2 (n = 86) | 2.643 (1.443–4.482) | 0.002 | |
pTNM staging | 0.145 | ||
I (n = 43) | Reference | ||
II (n = 38) | 1.636 (0.739–3.622) | 0.224 | |
III (n = 30) | 0.543 (0.173–1.709) | 0.297 | |
IV (n = 61) | 1.602 (0.768–3.342) | 0.209 | |
T staging | 0.044 | ||
pT1 (n = 48) | Reference | ||
pT2a (n = 38) | 1.809 (0.866–3.777) | 0.114 | |
pT2b (n = 14) | 2.344 (0.929–5.913) | 0.071 | |
pT3 (n = 47) | 0.941 (0.420–2.107) | 0.883 | |
pT4 (n = 25) | 0.433 (0.123–1.524) | 0.192 | |
N staging | pN0 (n = 133) | ||
pN1 (n = 39) | 2.328 (1.304–4.157) | 0.004 | |
M staging | pM0 (n = 161) | ||
pM1 (n = 11) | 1.482 (0.533–4.118) | 0.451 | |
Gross type | 0.076 | ||
Mass forming (n = 141) | Reference | ||
Periductal infiltrative (n = 8) | 0 | 0.964 | |
Intraductal growth (n = 18) | 0.134 (0.018–0.971) | 0.047 | |
Mixed (n = 5) | 2.672 (0.827–8.638) | 0.101 | |
Lymphatic emboli | Absent (n = 102) | ||
Present (n = 70) | 2.519 (1.429–4.438) | 0.001 | |
Vascular invasion | Absent (n = 95) | ||
Present (n = 77) | 1.111 (0.634–1.945) | 0.714 | |
Perineural invasion | Absent (n = 118) | ||
Present (n = 54) | 0.386 (0.181–0.822) | 0.014 | |
Tumor border | Expanding (n = 32) | ||
Infiltrative (n = 140) | 2.133 (0.846–5.375) | 0.108 | |
Tumor differentiation | 0.083 | ||
Well (n = 23) | Reference | ||
Moderate (n = 94) | 9.405 (1.283–68.943) | 0.027 | |
Poor (n = 55) | 9.671 (1.290–72.518) | 0.027 | |
Chemotherapy and/or radiotherapy | No (n = 120) | ||
Yes (n = 52) | 0.979 (0.534–1.792) | 0.944 |